Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Atom electric cars are already available for booking

7/31/23 KMAZ

Noventiq applied for delisting of receipts from the Moscow Exchange

7/31/23 SFTL

Stavropolenergosbyt reported for 6 months of 2023 by RAS

7/31/23 STSB

Lukoil reported for 6 months of 2023 by RAS

7/31/23 LKOH

Rosseti Center and Volga Region reported for 6 months of 2023 by RAS

7/31/23 MRKP

Cherkizovo Group is ready to supply sausages and nuggets to Africa

7/31/23 GCHE

Rosinter Restaurants Holding reported for 6 months of 2023 by RAS

7/31/23 ROST

Sollers reported for 6 months of 2023 by RAS

7/31/23 SVAV

Nizhnekamskshina reported for 6 months of 2023 by RAS

7/31/23 NKSH

Chelyabinsk Forging and Pressing Plant reported for 6 months of 2023 by RAS

7/31/23 CHKZ